| Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas. | |
| | |
MedLine Citation:
|
PMID: 15152279 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: Gastrointestinal and pancreatic fistulas are characterized as serious complications following abdominal surgery, with a reported incidence of up to 27% and 46%, respectively. Fistula formation results in prolonged hospitalization, increased morbidity/mortality and increased treatment costs. Conservative and surgical approaches are both employed in the management of these fistulas. The purpose of the present study was to assess, evaluate and compare the potential clinical benefit and cost effectiveness of pharmacotherapy (somatostatin versus its analogue octreotide) versus conventional therapy. PATIENTS AND METHODS: Fifty-one patients with gastrointestinal or pancreatic fistulas were randomized to three treatment groups: 19 patients received 6000 IU/day of somatostatin intravenously, 17 received 100 microg of octreotide three times daily subcutaneously and 15 patients received only standard medical treatment. RESULTS: The fistula closure rate was 84% in the somatostatin group, 65% in the octreotide group and 27% in the control group. These differences were of statistical significance (P=0.007). Overall mortality rate was less than 5% and statistically significant differences in mortality among the three groups could not be established. Overall, treatment with somatostatin and octreotide was more cost effective than conventional therapy (control group), and somatostatin was more cost effective than octreotide. The average hospital stay was 21.6 days, 27.0 and 31.5 days for the somatostatin, octreotide and control groups, respectively. CONCLUSIONS: Data suggest that pharmacotherapy reduces the costs involved in fistula management (by reducing hospitalization) and also offers increased spontaneous closure rate. Further prospective studies focusing on the above parameters are needed to demonstrate the clinicoeconomic benefits. |
| | |
Authors:
|
Emanuel Leandros; Pantelis T Antonakis; Konstantinos Albanopoulos; Chris Dervenis; Manousos M Konstadoulakis |
Related Documents
:
|
8317979 - The resource implications of severe necrotizing pancreatitis treated by necrosectomy. 16500389 - Efficacy and safety of therapeutic ercp in patients 90 years of age and older. 15832419 - Extended radical operation of pancreatic head cancer: appraisal of its clinical signifi... 10875989 - The feasibility of spleen-preserving pancreatectomy for end-stage chronic pancreatitis. 23419449 - Effects on the quality of compression-only, cardiopulmonary resuscitation performance a... 7110819 - Persistent neonatal hypoglycemia due to hyperinsulinism: medical aspects. 10865969 - Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with ac... 14612859 - Selective use of the intensive care unit after elective infrarenal abdominal aortic ane... 8790569 - Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis b. ... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Canadian journal of gastroenterology = Journal canadien de gastroenterologie Volume: 18 ISSN: 0835-7900 ISO Abbreviation: Can. J. Gastroenterol. Publication Date: 2004 May |
Date Detail:
|
Created Date: 2004-05-20 Completed Date: 2004-09-02 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8807867 Medline TA: Can J Gastroenterol Country: Canada |
Other Details:
|
Languages: eng Pagination: 303-6 Citation Subset: IM |
Affiliation:
|
Hippocration Hospital, Athens Medical School, Athens, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abdomen
/
surgery Aged Costs and Cost Analysis Female Gastric Fistula / drug therapy*, economics, etiology Gastrointestinal Agents / economics, therapeutic use* Humans Intestinal Fistula / drug therapy*, economics, etiology Length of Stay / economics Male Middle Aged Octreotide / economics, therapeutic use* Pancreatic Fistula / drug therapy*, economics, etiology Postoperative Complications Somatostatin / economics, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Gastrointestinal Agents; 51110-01-1/Somatostatin; 83150-76-9/Octreotide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Helicobacter pylori and the prevention of gastric cancer.
Next Document: Serum beta2-microglobulin levels in hepatitis B e antigen-negative chronic hepatitis B patients unde...